1. Products
  2. Solutions
  3. Insights+
  4. News & content
  5. About
  1. Launch
Book a demo
-
  1. My Preqin
  1. Products
  2. Solutions
  3. Insights+
  4. News & content
  5. About
  1. Launch
  1. My Preqin
Book a demo

Tavotek

Have updates for this profile?  Please contribute data

About
= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

Year established

2019

Location

PA US

Primary Industry

Biotechnology

About

Founded in 2019 and based in Suzhou, China. Tavotek is an innovative large-molecule biopharmaceutical developer who focuses on the development of therapeutic medicines for patients. The company's Chief Operations Officer Mr. Wei Zhang was the head of Digital Health and Information Technology at the Johnson and Johnson (J&J) before joining in the company. The company has 3 R&D platform for biologics include Phage Display Library, Engineering platform for tissue-specific biologics, and Multicyclic peptide platform. Along with these platforms, it has a pipeline of product candidates focused on cancers, autoimmune conditions, and infectious diseases in various stages of development.
Current Investors
GF Xinde Investment, Tsing Song Capital, Lanhu Capital

Request a demo to show more

Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.tavotek.com
Company Stage
Series B
Total Amount Raised
Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.
Sign in Request demo